Bristol Myers Squibb (BMY) Other Accumulated Expenses (2009 - 2026)

Bristol Myers Squibb has disclosed Other Accumulated Expenses across 16 years of filings, most recently posting $12.6 billion for Q1 2026.

• In Q1 2026, Other Accumulated Expenses fell 23.6% year-over-year to $12.6 billion; the TTM figure through Mar 2026 stood at $12.6 billion (down 23.6% YoY), while the FY2025 annual figure was $17.6 billion, down 3.01% from the prior year.
• Other Accumulated Expenses slipped to $12.6 billion in Q1 2026, from $17.6 billion in the prior quarter.
• Over the last five years, Other Accumulated Expenses for BMY reached as high as $19.3 billion in Q3 2025 and fell as low as $12.4 billion in Q1 2022.
• The 5-year median for Other Accumulated Expenses is $15.9 billion (2023), against an average of $15.5 billion.
• Annual changes were most pronounced in 2024 — Other Accumulated Expenses gained 22.48% — and 2026, when it declined 23.6%.
• A 5-year view of Other Accumulated Expenses shows it stood at $14.6 billion in 2022, then gained by 8.9% to $15.9 billion in 2023, then rose by 14.11% to $18.1 billion in 2024, then fell by 3.01% to $17.6 billion in 2025, then dropped by 28.24% to $12.6 billion in 2026.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $12.6 billion, $17.6 billion, and $19.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.